Rocket Lab vs. Firefly Aerospace: Which Stock Is More Attractive?

The article favors Firefly Aerospace over Rocket Lab, citing projected 2026 sales growth of 173.12% to $436.60 million versus Rocket Lab’s 58.25% growth to $952.35 million, and lower forward price-to-sales multiples of 4.72 versus 25.96. Both stocks fell over the past three months—5.5% for Firefly and 15.7% for Rocket Lab—while Firefly carries a Zacks Rank #2 (Buy) and Rocket Lab a #3 (Hold). Rocket Lab completed its 98th Electron launch on Oct. 23, 2026; Firefly subsidiary SciTec added $1.5 million to a U.S. Air Force contract, bringing its total value to $31 million.

Analysis

The headline comparison favors FLY on growth and sales multiple, but that spread is not automatically mispricing: the cited Air Force contract expansion is a small program increment, not evidence that SciTec can materially change consolidated earnings, while Rocket Lab’s launch record does not de-risk Neutron execution. FLY’s faster projected growth may also reflect a smaller base; verify organic growth, backlog conversion, cash burn and share-count trends before treating the lower P/S as a margin of safety. Those details are absent.

Near term, the article offers little new earnings information: a successful Electron mission supports execution credibility, while the SciTec award is more useful as evidence of program extension than as a revenue catalyst. Over 1–3 months, watch company guidance, funded backlog and cash conversion. Over 6–18 months, the key relative driver is whether FLY converts development programs into repeatable launches and government revenue, versus whether RKLB advances Neutron without schedule or funding slippage. A Neutron delay could compress RKLB’s premium; FLY launch or program setbacks could make its discount deserved. HAWK may benefit operationally from dependable deployment capacity, but a single customer relationship does not establish material earnings sensitivity.

Contrarian view: Rocket Lab’s premium may partly reflect broader systems exposure and execution history, so a simple sales-multiple comparison understates business-quality differences. Conversely, FLY’s faster estimated growth and lower multiple may already price in successful execution. Net: relative-value setup, not a high-conviction sector call.

Key Decisions for Investors

• Do not chase either name on this article alone. Before initiating, compare organic revenue growth, funded backlog, cash burn and dilution using current filings; the article’s sales estimates and P/S multiples do not resolve those risks.
• Consider a small, event-driven FLY-over-RKLB relative-value position only after confirming FLY’s growth is converting to cash and its launch schedule remains intact. Keep exposure limited; FLY’s cheaper multiple is not protection against execution failure.
• For the next 1–3 months, monitor guidance and backlog conversion at both companies, plus any change to Neutron milestones. A material FLY schedule slip or weakening cash conversion falsifies the relative-long thesis; a Rocket Lab Neutron delay or estimate reduction strengthens it.
• Avoid treating the SciTec contract expansion as a standalone earnings catalyst. Reassess only if subsequent awards and reported defense revenue show repeatable, material growth.